Compare Essex Property Trust, Inc. (ESS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Novartis AG — how do they compare? Essex Property Trust, Inc. trades at $271.57 (market cap $17.26B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 15.6× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Novartis AG for 82 Days on average.
| ESS | NVS | |
|---|---|---|
Market Cap | $17.26B | $268.57B |
Volume | 454,464 | 1,532,573 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $168.62 |
52-Week Low | $239.61 | $121.80 |
Typical Hold Time | 111 Days | 82 Days |
Enterprise Value | $23.86B | $309.89B |
Dividend Yield | 3.86% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $271.57, up 1.31% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 results beating FFO guidance and raised full-year outlook, while resolving major litigation. Fundamentals show solid revenue growth to $1.89B in 2025 with 21.48% net margins, though valuation multiples remain elevated with P/E of 41.83.
Outlook remains cautiously optimistic with analyst consensus target of $303.41 offering 12% upside potential. Key opportunities include sustained West Coast multifamily demand and operational efficiency, while risks involve elevated debt levels and potential regional economic headwinds affecting rental markets.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
